Equillium (EQ)

• Market cap: $21.2M
• 1 day: -1.64%
• 5 days: -6.56%
• 1 month: -19.19%
• 3 months: -25.15%
• 6 months: -12.15%
• Year to date: -18.56%
• 1 year: -5.68%
• 5 years: -86.35%
• 10 years: -95.73%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Employees: 45

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

15% more capital invested

Capital invested by funds: $4.96M [Q2] → $5.72M (+$759K) [Q3]

4% more funds holding

Funds holding: 25 [Q2] → 26 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.85% less ownership

Funds ownership: 20.31% [Q2] → 19.46% (-0.85%) [Q3]

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5